AstraZeneca stock consolidates amid mixed clinical trial results and new oncology partnership

Traders Union
All News
Stocks
AstraZeneca slides 0.18% to GBX11,976

Highlights

AstraZeneca reported its Phase III HICKORY trial for efzimfotase alfa did not meet the primary endpoint, raising regulatory uncertainty for future revenue.
AstraZeneca expanded its pipeline with a joint oncology programme with Summit Therapeutics and the opening of a new US R&D centre.
Shares of AstraZeneca trade below key moving averages with weak momentum signals, and the short-term price range is GBX11,798 to GBX12,153 with high probability of further downside.

Regulatory setbacks offset innovation gains amid pipeline expansion

AstraZeneca presented results from the Phase III HICKORY trial of efzimfotase alfa for hypophosphatasia, with findings showing that the primary endpoint was not met, while secondary measures improved and the drug remains under regulatory review, according to Benzinga. This outcome introduces regulatory uncertainty for potential future revenue from efzimfotase alfa, weighing on near-term sentiment. Separately, AstraZeneca took a significant stake in Summit Therapeutics and formed a joint oncology programme addressing clinical studies in gastrointestinal tumors, according to Kalkinemedia, and also opened a major new R&D centre in the US, noted by Pmlive. These developments expand the pipeline and strengthen longer-term innovation, though price action has remained under broader selling pressure.

Technical weakness persists as momentum indicators oversold

On the technical front, AZN is trading beneath its MA-20 at GBX12,019 and MA-50 at GBX12,008 on the hourly chart, with the daily MA-200 at GBX13,518 forming longer-term overhead resistance. The Ichimoku Kijun sits at GBX12,007 as the nearest upside cap, while momentum remains negative: both the MACD and Awesome Oscillator indicate a sell bias and the ADX is neutral. Intraday, oscillators including the RSI at 44.9, Stochastic RSI, and CCI are oversold, and Bull/Bear Power continues to point toward seller dominance. This suggests technical weakness, though short-term selling pressure shows signs of being overstretched on oscillators.

Downside risk elevated as breakout probability remains subdued

In the short term, the expected price range for AZN is GBX11,798 to GBX12,153, reflecting the typical volatility band relative to current levels. The probability of an upward breakout is very low, whereas the risk of a downward continuation is high. If the price remains within this corridor, sideways consolidation is likely; a move above GBX12,007 would open the door to a bullish scenario, while a close below GBX11,798 would signal further downside.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca’s technical setup as weak, with price action under sustained pressure and no bullish momentum. He notes that regulatory uncertainty from the Phase III trial is curbing sentiment, despite new R&D investments and pipeline deals. The analyst believes any upside is capped while major resistance levels hold. "Unless AZN reclaims GBX12,007 with strong momentum, I remain on the defensive and see further downside risk prevailing."

Earlier, analysts noted that AstraZeneca shares remained under technical pressure despite pipeline developments, with downside risks seen as the prevailing scenario. This latest update strengthens that view, as persistent weakness below key moving averages and continued negative momentum keep downside continuation the key scenario to watch.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.